Accesswire
19 Jun 2026, 22:00 UTC · 18w ago
Impact · against what's priced in
Onco-Innovations has successfully derisked the manufacturing process for ONC010 by producing a high-purity API batch at scale. This technical milestone reduces the execution risk associated with moving toward IND-enabling studies and First-in-Human trials.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Onco-Innovations successfully completed a 300g scale-up batch of the API for its drug candidate ONC010 with 99.3% purity.
More positive than 93% of claims this week
The completed API batch will support ongoing IND-enabling activities and the path toward First-in-Human evaluation.
Continue reading
5 related stories
The completion of a 300g API batch with 99.3% purity demonstrates manufacturing scalability and process control, which are critical prerequisites for regulatory filing and clinical entry.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 78% of claims this week
The company appointed Dave Antony as the new Chief Financial Officer and Corporate Secretary, replacing Nico Mah.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company achieved a significant manufacturing milestone with high-purity API scale-up for its lead drug candidate and appointed a new CFO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
−57.7%
Price is moving against the score
$0.3991 vs $0.9439 close before publication (Jun 18) · not market-adjusted
ONCO chart →
